Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
1.58 (USD) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0.725 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | -0.725 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 31,419,817 | 18.948 | 4.852 | 0.295 | 0.196 | 0.946 |
| General & Administrative Expenses
| 8,083,819 | 5.359 | 5.253 | 2.14 | 0.181 | 0.176 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 8,083,819 | 5.359 | 5.253 | 2.14 | 0.181 | 0.176 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | -0 |
| Operating Expenses
| 39,503,636 | 24.307 | 10.105 | 2.435 | 0.377 | 1.122 |
| Operating Income
| -39,503,636 | -24.307 | -10.105 | -2.435 | -0.377 | -1.122 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 39,503,596.756 | -0.012 | 1.589 | -1.348 | -0.469 | -0.558 |
| Income Before Tax
| -39.244 | -24.319 | -8.516 | -3.783 | -0.846 | -1.68 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -16,949 | 0.021 | 0.006 | 0.001 | 0.001 | 0.001 |
| Net Income
| -39,260,837 | -24.339 | -8.522 | -3.783 | -0.847 | -1.68 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0 |
| EPS Diluted
| -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0 |
| EBITDA
| -39,503,636 | -24.112 | -10.105 | -2.329 | -0.376 | -1.121 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |